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Methods: Using nationwide administrative registries in Denmark from 2000-2009 we
sought to describe the use of various lower extremity imaging modalities (CTA, MRA,
angiography, and Doppler ultrasound) 1-year prior to lower extremity amputation.
Analysis was limited to patients > 40 years with first amputation for a primary
diagnosis of lower extremity peripheral arterial disease (PAD) or diabetes (DM).
Results: Among the 7,748 patients (58.5% male, mean age 74.1 + 11.6 years) that
underwent an amputation, 5,607 had PAD and 2,141 had DM as the primary cause for
amputation. Use of imaging modalities 1-year prior to amputation was modest; nearly
2/3rd of the amputations were performed without imaging 1 year prior to surgery
(Table). One-year mortality was 33% among patients who were imaged vs 40% among
those who were not. Overall, one-year mortality was 38% (29% for DM and 42% for
PAD).
Rates of Imaging 1-Year Prior to Amputation
Conclusion: The most common imaging modality used 1-year prior to amputation for
PAD or DM was angiography. However, most amputations occur without any imaging
1-year prior to surgery; this represents an opportunity to identify anatomical severity
and modify treatment, especially given the high mortality after amputation.
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Paradigm Shift in Ruptured AAA (RAAA) Management; Twelve years
experience in a tertiary referral centre of Endovascular repair of
RAAA(REVAR) vs open repair (OR)
Sherif Sultan1, 2, Wael Tawfick1, Niamh Hynes2, 1
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2Galway Clinic, Galway, Ireland
Background: Out of 683 AAA operated upon, 120 patients presented with RAAA over
12 years, 42 had REVAR and 78 had OR.
Methods: During 20th century 95% of all AAA were done surgically. However during
21st century 80% of AAA is done endovascularly. Mean Annual number of OR dropped
from 19+/-3.6 to 18+/-7.8,P<0.845, however Mean Annual number of EVARs had
rocketed to 26+/-6.1 P<0.006 . Overall number of AAA repairs has increased by 65%
over twelve years period and number of EVAR has increased by 80% but the absolute
number of RAAA had declined.
Results: Total Emergency mortality rate decreased from 64% to 28.2%. Low Mortality
Rate of 16%for REVAR Vs 32%in OR is due to introduction of an REVAR Programme
which constitutes screening for prevention with early intervention and REVAR for
rupture which has an absolute perioperative mortality reduction of 49% over OR. Table
5 years Survival of Patients with RAAA were 75% REVAR vs. 60% OR (p=0.0205)
Conclusion: Para-Millennium and Contemporary Trends in AAA Management had
shown Increased in Elective EVAR which increased the mortality advantage in favour
of REVAR and it should be Gold standard for RAAA.
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Results of the U.S. IDE Study of the Wildcat Catheter (CONNECT)
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Background: Percutaneous techniques for crossing femoropopliteal chronic total
occlusions (CTOs) offer an alternative to bypass surgery in high-risk patients. The
Wildcat CTO catheter uses a rotating distal tip and deployable wedges to improve
operator device control and create more reliable true lumen passage. We report the
final results of 88 patients enrolled in the Wildcat catheter trial. The FDA recently
granted conditional approval for 50 additional patients which will be incorporated into
the presentation.
Methods: This is a prospective, multicenter, nonrandomized trial. Enrolled patients
with a CTO of the femoropopliteal arteries were unable to be successfully crossed with
initial guidewire techniques. The primary measured efficacy endpoint is guidewire
placement into the true distal lumen after Wildcat passage confirmed by angiography.
Secondary safety/efficacy endpoints were assessed within 30 days. Procedural site
reporting was independently ratified by board-certified angiographic reviewers.
Results: 88 patients were enrolled with an average CTO length of 174 ± 96mm, 89%
of which were de novo lesions. 55% of lesions demonstrated at least moderate
calcification and >85% of vessels were superficial femoral arteries. The device was
used in 84/88 patients. Successful CTO crossing was reported in 89.3% of cases with
95.2% freedom from major adverse events or clinically relevant complications (Table).
Primary Safety
Conclusion: The Wildcat CTO catheter demonstrated an 89.3% crossing rate with little
associated morbidity. Results surpassed study design endpoints.
TCT-600
The OCELOT Catheter for Long SFA Occlusions–The Six Months Follow Up
R. Stefan Kiesz1, Przemyslaw Nowakowski2, Stanislaw Trznadel2, Aleksander
Zurakowski2, Pawel Cwik2, Jacek Czarny2, Barbara Wiernek2, Magda Konkolewska1,
Pawel E Buszman2
1San Antonio Endovascular & Heart Institute, San Antonio, TX; 2American Heart of
Poland - Dep. of Vascular Surgery, Chrzanow, Poland
Background: The OCELOT catheter is an atherectomy device with integrated Optical
Coherence Tomography (OCT). By using OCELOT, the operator (while passing the
catheter through-out the occlusion), is oriented in which layer of the vessel he is at the
given moment. It allows to keep the device intraluminal without the subintimal
penetration.
Methods: In August 2010, 10 patients (9 male) with Chronic Total Occlusion (CTO)
of the SFA (length of occlusion between 50-100mm) and claudication distance <200m
underwent 10 endovascular procedures with the use of the OCELOT catheter.
Results: The procedural success was 90%. In one case we were unable to cross the
occlusion because of the severe calcification of the artery. Balloon Angioplasty alone
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was performed in 5, and stents were implanted in 4 cases. In all patients clinical
improvement was observed, with palpable popliteal/foot pulses. In the 30-day
observation, 1 case of subcutaneous hematoma was observed that did not require
surgical treatment. In further observation, the patient underwent revision of the
popliteal artery without bypass surgery. 2 months after the procedure, one patient
underwent balloon angioplasty of the Common Femoral Artery bifurcation without
any intervention on the previously stented segment of the SFA. 4 months after the
procedure, another patient developed recurrent claudication with angiographically
confirmed long SFA occlusion. The recanalization attempt was unsuccessful. In
February 2011, 8 patients underwent control angiography to assess the patency of the
treated SFA segment and, when needed, to qualify them for the next stage procedure.
In 5 patients there was no significant restenosis at the treated segment, in 3 cases such
changes were found and they required a balloon angioplasty without stent implantation.
Conclusion: OCELOT catheter is a novel device and can be safely use for
recanalization of the occluded arteries. It allows, with high efficiency, to avoid
subintimal angioplasty and may reduce the need of stent implantation. Further
observations will help to assess the long term results. It seems reasonable to use Drug
Eluting Balloons in next studies.
TCT-601
Midterm Outcomes of S.M.A.R.T. Self-Expanding Nitinol Stent Implantation
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Background: Although endovascular treatment (EVT) became first-line therapy for
peripheral artery disease (PAD), superficial femoral artery (SFA) lesion is still
controversial especially in complex lesion such as chronic total occlusion (CTO). We
investigated midterm patency rate and predictor of restenosis after S.M.A.R.T. self-
expanding nitinol stent implantation for CTO in SFA lesion over large multicenter
registry data.
Methods: From March 2003 to December 2009, serial 940 arteriosclerosis obliterans
patients, 1087 limbs had EVT implanted self-expanding nitinol stent for SFA at 4
hospitals in Japan. Of the cohort, 347 patients 379 limbs implanted S.M.A.R.T. self-
expanding nitinol stent for CTO in SFA and followed for 5 years. We retrospectively
investigated the outcomes, primary and secondary patency rate using Kaplan-Meier
method with logrank test, multivariate analysis used to predict factors associated with
restenosis.
Results: Mean age was 73±9.4 years and female was 32%. Fifty nine percent of
patients had diabetes mellitus, 12% of patients required hemodialysis and 24% was
critical limbs ischemia patients. Average ABI before procedure was 0.56±0.20. In lesion
morphology, occluded length was 195±89 mm, 26% was TASC II AB and 74% was
TASC II CD lesion. Also, reference vessel diameter was 5.4±0.8mm. Mean total stent
length was 198±87 mm, mean stent diameter was 7.0±1.0mm. In the clinical outcomes
13 limbs (3.4%) had major amputation and 9 limbs (2.4%) went to surgery. Forty eight
limbs, 13% detected stent fracture through study period. Five years primary and
secondary patency rate was 68% and 97%, respectively. On multivariate analysis,
female gender (odds ratio, 2.41; p=0.0006), renal insufficiency requiring hemodialysis
(odds ratio, 3.01; p=0.0023), administration of cilostazole (odds ratio, 0.60; p=0.0372),
stent fracture (odds ratio, 2.37; p=0.0131), was the factors associated with restenosis.
Conclusion: Patency rate after S.M.A.R.T. self-expanding nitinol stent implantation
for CTO in SFA lesion up to 5 years seems acceptable. Strong atherosclerotic agents
may associate with restenosis and new stent device tolerate with physical stress,
administration of cilostazole may improve the outcomes.
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Matrix metalloproteinases can predict the progression of non-culprit lesion
Konstantinos Toutouzas, Dimitrios Klettas, Andreas Synetos, Antonis Karanasos,
Chrysoula Patsa, Anastasios Spanos, Dimitrios Tousoulis, Christodoulos Stefanadis
First Department of Cardiology, University of Athens, Athens, Greece
Background: Matrix metalloproteinase (MMP-9) not only is involved in both
inflammation and matrix degradation but also is prevalent in the arterial wall
throughout the arterial system. The CD40-CD40L system is a pathway which is
associated with both prothrombotic and proinflammatory effects. The soluble form of
CD40L (sCD40L) is derived mainly from activated platelets and contributes to the
pathophysiology of atherosclerosis. We hypothesized that MMP-9 and sCD40L may
mediate in the development and progression of atherosclerotic lesions. The aim of the
study is to explore the association between serum levels of MMP-9 and sCD40L and
the development and progression of non culprit lesions in patients with coronary artery
disease(CAD).
Methods: We included 80 patients (64 men and 16 women) who underwent two
coronary angiograms with a time interval greater than three months. The culprit lesion
of the first angiogram was clearly identified by a combination of ECG, wall motion
abnormalities, scintigraphic perfusion defects and coronary angiogram. All patients
underwent percutaneous coronary intervention as a treatment for the culprit lesion. In
the second coronary angiography we investigated whether they had a new culprit lesion
clearly differentiated from the culprit lesion of the first angiogram. Samples for plasma
were obtained on admission before the second angiography in all patients. MMP-9 and
sCD40L were assessed by enzyme-linked immunosorbent assay.
Results: In 43 cases was observed progression of the non culprit lesions between the
two angiograms. The mean follow up period was 48 ± 12 months. Mean concentration
of sCD40L was not associated with the progression of the non culprit lesions of the
coronary arteries. However significant association of serum levels of the MMP-9 and
the progression of the non culprit lesions in the coronary arteries was observed. The
subjects with progression of the non culprit lesions had increased mean serum
concentration of MMP-9 in comparison with those that didn’t have any plaque
progression during the follow up period (9.56 ±4.54 ng/L versus 7.43 ±3.23 ng/L,
p=0.007).
Conclusion: The mean concentration of serum levels of MMP-9 in this study was
related to progression of the non culprit lesions in coronary arteries in contrast with
serum levels of sCD40L that seem not to be associated.
TCT-603
Incidence, Morphological Pattern, and Time Course of Peri-stent Contrast
Staining
Haruki Eguchi, Kazushige Kadota, Yuki Hayakawa, Naoki Saito, Suguru Otsuru,
Daiji Hasegawa, Hidekazu Shigemoto, Takeshi Tada, Seiji Habara, Naoki Oka,
Harumi Kato, Yasushi Huku, Hiroyuki Tanaka, Hiroyuki Yamamoto, Tsuyoshi Goto,
Kazuaki Mitsudo
Cardiology, Kurashiki Central Hospital, Kurashiki, Japan
Background: Peri-stent contrast staining (PSS) is an abnormal angiographic finding
at the stent implantation site suggesting contrast staining outside the stent struts, which
does not fulfill the classical definition of coronary artery aneurysm. Imai et al. reported
that PSS found after sirolimus-eluting stent implantation appeared to be associated
with very late stent thrombosis (VLST). However, differences in incidence,
morphological pattern, and time course of PSS between drug-eluting stent (DES) and
bare metal stent (BMS) remain unknown.
Methods: We retrospectively analyzed 6872 lesions with stent implantation from 2001
to 2008. PSS was defined as contrast staining outside the stent contour extending to
20% of the stent diameter. A morphological classification of PSS included monofocal,
multifocal, segmental with irregular, and segmental with smooth. Time course was
classified three types (Regression, no change, progression)
Results: PSS was observed in 131 (1.9%) of the 6872 lesions: BMS, 2.2% (29/1345);
DES, 1.9% (102/5528); p=ns. As shown in the table, however, there were differences
in morphological pattern and time course. Morphologically, monofocal of PSS was
observed more frequent in BMS, and segmental irregular was more frequent in DES.
Regarding the time course, regression type was dominant in BMS. VLST occurred in
6 PSS lesions, of which 4 were segmental irregular and 5 were progression type. No
stent thrombosis occurred in BMS.
Incidence, Morphological Pattern, and Time Course of PSS Between BMS and DES
Conclusion: Although there was no difference in the incidence of PSS between BMS
and DES, morphological pattern and time course were different.
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